Pramipex 0.25 mg (Pramipexole)

Price range: 43.75$ through 63.75$

Product Overview Pramipex 0.25 mg is a prescription tablet produced by Sun Pharmaceutical Industries Ltd. Each strip contains ten tablets, and the product is available in pack sizes of 60, 90, or 120 tablets. The active ingredient is pramipexole, a n

Active Ingredients	Pramipexole
Delivery Time	6 To 15 days
Indication	Parkinson's disease, Restless leg syndrome
Manufacturer	Sun Pharmaceutical Industries Ltd
Packaging	10 tablets in 1 strip
Strength	0.25mg

Estimated Delivery: Fri, Oct 09 – Sun, Oct 11

... people are viewing this right now

Guaranteed Safe Checkout

Pack Size	Price	Quantity
60 Tablet/s	43.75$
90 Tablet/s	53.75$
120 Tablet/s	63.75$

🚚 Worldwide Shipping — Fully Tracked & Insured

United States

Standard tracked delivery

7–14 Business Days

United Kingdom

Standard tracked delivery

5–10 Business Days

Australia

Standard tracked delivery

10–18 Business Days

Rest of World

50+ countries available

10–20 Business Days

All orders are shipped in plain, discreet packaging with no pharmacy or medicine reference outside. Tracking number is sent by email after dispatch. Shipped from Mumbai, India.

Description

Product Overview

Pramipex 0.25 mg is a prescription tablet produced by Sun Pharmaceutical Industries Ltd. Each strip contains ten tablets, and the product is available in pack sizes of 60, 90, or 120 tablets. The active ingredient is pramipexole, a non‑ergoline dopamine agonist formulated at a strength of 0.25 mg per tablet. The medication is supplied in a blister strip that protects each tablet from moisture and light, ensuring stability throughout the shipping period of six to fifteen days. This formulation is intended for oral use and is marketed for the treatment of Parkinson’s disease and restless leg syndrome. The packaging reflects a commercial focus on bulk purchasing while maintaining patient‑friendly presentation.

What is Pramipex 0.25 mg (Pramipexole)

Pramipex 0.25 mg refers to the dosage strength of pramipexole, the active pharmaceutical ingredient (API) that belongs to the class of non‑ergoline dopamine agonists. The drug works by stimulating dopamine D3 and D2 receptors in the striatum, thereby enhancing dopaminergic transmission that is deficient in Parkinson’s disease. In addition to its central nervous system activity, pramipexole has been shown to modulate sensory pathways involved in the urge to move the legs, making it effective for restless leg syndrome. The medication is manufactured under the quality standards of Sun Pharmaceutical, a company with a global reputation for producing affordable yet rigorously tested generics. The 0.25 mg tablet is often used as a starting dose, allowing clinicians to titrate upward based on patient response and tolerability.

Uses and Benefits

Clinically, pramipex 0.25 mg is approved for two primary indications: Parkinson’s disease and moderate to severe restless leg syndrome. In Parkinson’s disease, the agent helps to reduce motor fluctuations, tremor, rigidity, and bradykinesia, enabling patients to maintain higher functional mobility for a longer period. For restless leg syndrome, the medication alleviates the uncomfortable sensations in the limbs that typically occur at night, improving sleep quality and reducing the frequency of involuntary leg movements. Patients often report a noticeable improvement in daily activities, such as walking, dressing, and driving, after consistent use of the prescribed regimen. The commercial advantage of this product lies in its availability in multiple pack sizes, allowing patients and caregivers to purchase an appropriate quantity without unnecessary waste.

How It Works

The pharmacological mechanism of pramipexole centers on its high affinity for dopamine D3 receptors and moderate affinity for D2 receptors, both of which are integral to the basal ganglia circuitry that coordinates movement. By binding to these receptors, pramipexole mimics the action of dopamine, compensating for the loss of endogenous neurotransmitter in Parkinson’s disease. This agonist activity leads to increased neuronal firing in the direct pathway, facilitating smoother motor output. In restless leg syndrome, the same dopaminergic modulation reduces the abnormal sensory signals that trigger the urge to move the legs, thereby decreasing the incidence of periodic limb movements during sleep. The drug’s pharmacokinetics involve rapid absorption, peak plasma concentrations within one to two hours, and a half‑life of approximately five to six hours, which supports twice‑dayly dosing in most treatment protocols.

Dosage Guidelines

Treatment typically begins with one tablet of pramipex 0.25 mg taken once daily, often in the evening to align with the natural circadian pattern of symptom worsening. After one week, the dose may be increased to 0.5 mg per day, and subsequent increments of 0.5 mg can be made at weekly intervals, depending on clinical response and side‑effect profile. The maximum recommended daily dose for Parkinson’s disease is 4.5 mg, divided into three separate administrations, while for restless leg syndrome the ceiling is generally 1.5 mg per day. Tablets should be swallowed whole with water and may be taken with or without food; however, taking the medication with a small snack can help reduce gastrointestinal discomfort. Patients are advised to store the medication at room temperature, away from moisture and heat, and to keep the strip sealed until ready for use. It is essential to follow the prescribing physician’s instructions precisely, as dosing adjustments may be necessary for individuals with renal impairment or elderly patients.

Side Effects

Like all dopaminergic agents, pramipex 0.25 mg can be associated with a range of side effects, most of which are mild to moderate and transient. Common adverse reactions include nausea, dizziness, somnolence, constipation, and occasional headache. Less frequent but clinically important events comprise orthostatic hypotension, impulse control disorders such as compulsive gambling or eating, and rare cases of hallucinations. Patients should be monitored for signs of sudden drops in blood pressure, especially when rising from a seated position. If any of these symptoms persist or worsen, medical attention should be sought promptly. For more detailed information on safety data, refer to the official prescribing information or reputable medical databases such as NIH and Drugs.com.

Warnings and Precautions

Before initiating therapy with pramipex 0.25 mg, clinicians should assess renal function, as dose reduction is recommended for patients with moderate to severe kidney disease. The medication is contraindicated in individuals with a known hypersensitivity to pramipexole or any of the inactive ingredients. Caution is advised when prescribing to patients with a history of psychiatric disorders, as dopaminergic agonists have been linked to rare but serious neuropsychiatric events. Drug interactions may occur with other centrally acting agents, particularly those that affect serotonin or norepinephrine pathways, potentially increasing the risk of adverse effects. Pregnant or breastfeeding women should only use the medication if the expected benefit justifies the potential risk, and a discussion with a healthcare professional is essential. Additional safety guidance can be found on authoritative consumer sites such as MedlinePlus.

Frequently Asked Questions

What is the typical starting dose of pramipex 0.25 mg?

Most clinicians begin treatment with a single 0.25 mg tablet taken once daily, usually in the evening. After about one week, the dose may be increased gradually based on patient response and tolerability.

Can pramipex 0.25 mg be taken with food?

Yes, the tablet can be taken with or without food. Taking it with a light snack may help reduce stomach upset, especially during the initial titration phase.

How long does it take to notice improvement in symptoms?

Patients often report a modest reduction in motor symptoms or leg discomfort after one to two weeks of consistent dosing, although the full therapeutic effect may require several weeks to months.

Is there a risk of impulse‑control disorders?

Yes, dopaminergic agents like pramipexole have been associated with compulsive behaviors such as gambling, eating, or hypersexuality. Patients should be monitored for any sudden changes in behavior and advised to report them promptly.

Where can I find more detailed prescribing information?

Comprehensive details regarding dosage, contraindications, and side‑effects are available in the official product label and on trusted medical resources such as the NIH, Drugs.com, and MedlinePlus.